BSX
stock Healthcare Medical DevicesOverall Mixed · 58%
- Fundamentals Strong
- Trajectory Steady
- Leadership Churning
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Bearish 0 of 5 trend signals bullishRSI 28 — oversold: selling looks stretched and may be due for a bounce.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jun 3
- Open
- $47.70
- +0.04%
- Close
- $47.70
- +0.04%
- Current
- $47.70
- Prev close
- $47.68
- Today
- 20.45M
- 3-mo avg
- 18.24M
Earningscalendar synced from Yahoo 57d ago
- Most recent
- Apr 2290 days ago
- Next expected
- Jul 29in 8 days
Recent earnings dates
- Apr 22 90 days ago
- Feb 4 167 days ago
- Oct 22, 2025 272 days ago
- Jul 23, 2025 363 days ago
Past earnings dates come from BSX’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 51d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), BSX’s fundamentals read as strong overall.
At 20.0x, the price is a reasonable multiple of the company's annual profit.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
This company pays no dividend, common for firms reinvesting their profits back into growth.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A 14.4% margin is solid, in the ordinary range for a profitable company.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A 11.9% return on equity is respectable, in the normal range.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A 6.6% return on assets is reasonable for a company of this kind.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
Not enough data to compute debt-to-equity.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 1.62, short-term assets comfortably cover short-term bills.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue grew 19.9% from the prior year: strong top-line expansion.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Net income grew 56.7% from the prior year: strong profit expansion.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 51d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B |
| Net income | $1.0B | $698.0M | $1.6B | $1.8B | $2.9B |
| Diluted EPS | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 |
| Dividend / share | — | — | — | — | — |
| Total assets | $32.2B | $32.5B | $35.1B | $39.4B | $43.7B |
| Total liabilities | — | — | — | — | — |
| Shareholder equity | $16.6B | $17.6B | $19.5B | $21.8B | $24.2B |
| Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1B | $4.2B | $4.6B | $4.7B | $5.1B | $5.1B | $5.3B | $5.2B |
| Net income | $322.0M | $468.0M | $563.0M | $672.0M | $795.0M | $755.0M | $670.0M | $1.3B |
| Diluted EPS | $0.22 | $0.32 | $0.38 | $0.45 | $0.53 | $0.51 | $0.45 | $0.90 |
| Dividend / share | — | — | — | — | — | — | — | — |
Leadershipsynced from SEC 58d ago
- Mahoney Michael F Chairman, President & CEO · Director
- Monson Jonathan EVP and CFO
- Brown Vance R EVP, GC and Corp. Secretary
- Butcher Arthur C EVP& Grp Pres, MedSurg & APAC
- Fitzgerald Joseph Michael EVP & Group Pres, Cardiology
- O'Connor Padraig Andrew EVP, Global Operations
- O'Sullivan Miriam SVP, Chief HR Officer
- Woodworth Emily SVP, Global Controller and CAO
- Habiger David C Director
- Ludwig Edward J Director
- Mega Jessica L Director
- Morano Susan E Director
- Pegus Cheryl Director
- Smith Cathy R Director
- Weber Christophe Pierre Director
- Wichmann David S Director
- Zane Ellen M Director
Officers and board are drawn from BSX’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- May 27 −12.5% one-day move
- May 18 +6.2% one-day move
- May 8 New 6-month low (-49% off peak)
- Apr 22 +9.0% one-day move
- Mar 30 −9.0% one-day move
- Mar 24 New 6-month low (-35% off peak)
- Feb 23 Officer or director change reported in an 8-K
- Feb 5 Officer or director change reported in an 8-K
- Feb 4 New 6-month low (-30% off peak)
- Feb 4 −17.6% one-day move
- Dec 31, 2025 FY2025 net income +57% YoY
- Dec 8, 2025 New 6-month low (-13% off peak)
- Nov 19, 2025 Officer or director change reported in an 8-K
- Oct 23, 2025 Officer or director change reported in an 8-K
- Sep 4, 2025 Officer or director change reported in an 8-K
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Recent SEC filingssynced from SEC 51d ago
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report